AAN 2023 | Dystonia: recent developments

Chantale Branson, MD, Morehouse School of Medicine, Atlanta, GA, discusses recent developments regarding dystonia. Recently, a network of biomarkers for botulinum toxin – DystoniaBoTXNet – has been developed. This network has an overall accuracy of 96.3% and an average speed of 19.2 seconds per case, outperforming other strategies. Clinical efficacy and cost still require evaluation. There have also been updates in nomenclature for dystonia regarding modes of inheritance and types of clinical clues. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.